New perspectives on parathyroid hormone therapy

Nancy E Lane, Stephen Morris

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose of review: The prevention and treatment of osteoporosis has traditionally involved the use of antiresorptive therapies. The introduction of parathyroid hormone, an anabolic agent that enhances bone formation, has been accompanied by new treatment strategies. This article reviews combination and sequential therapy approaches with parathyroid hormone and antiresorptive agents to optimize efficacy outcomes. Recent findings: The distinguishing features of the anabolic and antiresorptive therapies for the treatment of osteoporosis has led to the hypothesis that the appropriate use of both agents, either in sequence or in combination, may result in superior fracture protection compared with either anabolic or antiresorptive treatment alone. This enthusiasm has been tempered by the observations that the transition from daily bisphosphonate therapy may blunt the efficacy of teriparatide. By contrast, more recent studies suggest that once-weekly bisphosphonate therapy may provide a better option with parathyroid hormone either in combination or in sequence. These considerations are critical to understanding the benefits of sequential treatment (parathyroid hormone followed by an antiresorptive agent), which aims to maintain or build on the large gains in efficacy from short-term therapy with parathyroid hormone. Because patients may require an additional treatment course of parathyroid hormone in the future, the choice of antiresorptive agent should be carefully considered. In addition, more recent evidence suggests that the forms of parathyroid hormone may have important differences in action that influence combination and sequence outcomes. Summary: Combination and sequential therapy with parathyroid hormone offers new options to maximize efficacy in patients at risk for osteoporotic fracture.

Original languageEnglish (US)
Pages (from-to)467-474
Number of pages8
JournalCurrent Opinion in Rheumatology
Volume17
Issue number4
DOIs
StatePublished - Jul 2005

Fingerprint

Parathyroid Hormone
Bone Density Conservation Agents
Therapeutics
Diphosphonates
Osteoporosis
Teriparatide
Anabolic Agents
Osteoporotic Fractures
Osteogenesis

Keywords

  • Anabolic agent
  • Antiresorptive agent
  • Combination therapy
  • Parathyroid hormone
  • Sequential therapy

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

New perspectives on parathyroid hormone therapy. / Lane, Nancy E; Morris, Stephen.

In: Current Opinion in Rheumatology, Vol. 17, No. 4, 07.2005, p. 467-474.

Research output: Contribution to journalArticle

Lane, Nancy E ; Morris, Stephen. / New perspectives on parathyroid hormone therapy. In: Current Opinion in Rheumatology. 2005 ; Vol. 17, No. 4. pp. 467-474.
@article{07d3a16eb33246ad96d9206dec2989ec,
title = "New perspectives on parathyroid hormone therapy",
abstract = "Purpose of review: The prevention and treatment of osteoporosis has traditionally involved the use of antiresorptive therapies. The introduction of parathyroid hormone, an anabolic agent that enhances bone formation, has been accompanied by new treatment strategies. This article reviews combination and sequential therapy approaches with parathyroid hormone and antiresorptive agents to optimize efficacy outcomes. Recent findings: The distinguishing features of the anabolic and antiresorptive therapies for the treatment of osteoporosis has led to the hypothesis that the appropriate use of both agents, either in sequence or in combination, may result in superior fracture protection compared with either anabolic or antiresorptive treatment alone. This enthusiasm has been tempered by the observations that the transition from daily bisphosphonate therapy may blunt the efficacy of teriparatide. By contrast, more recent studies suggest that once-weekly bisphosphonate therapy may provide a better option with parathyroid hormone either in combination or in sequence. These considerations are critical to understanding the benefits of sequential treatment (parathyroid hormone followed by an antiresorptive agent), which aims to maintain or build on the large gains in efficacy from short-term therapy with parathyroid hormone. Because patients may require an additional treatment course of parathyroid hormone in the future, the choice of antiresorptive agent should be carefully considered. In addition, more recent evidence suggests that the forms of parathyroid hormone may have important differences in action that influence combination and sequence outcomes. Summary: Combination and sequential therapy with parathyroid hormone offers new options to maximize efficacy in patients at risk for osteoporotic fracture.",
keywords = "Anabolic agent, Antiresorptive agent, Combination therapy, Parathyroid hormone, Sequential therapy",
author = "Lane, {Nancy E} and Stephen Morris",
year = "2005",
month = "7",
doi = "10.1097/01.bor.0000166383.73153.cf",
language = "English (US)",
volume = "17",
pages = "467--474",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - New perspectives on parathyroid hormone therapy

AU - Lane, Nancy E

AU - Morris, Stephen

PY - 2005/7

Y1 - 2005/7

N2 - Purpose of review: The prevention and treatment of osteoporosis has traditionally involved the use of antiresorptive therapies. The introduction of parathyroid hormone, an anabolic agent that enhances bone formation, has been accompanied by new treatment strategies. This article reviews combination and sequential therapy approaches with parathyroid hormone and antiresorptive agents to optimize efficacy outcomes. Recent findings: The distinguishing features of the anabolic and antiresorptive therapies for the treatment of osteoporosis has led to the hypothesis that the appropriate use of both agents, either in sequence or in combination, may result in superior fracture protection compared with either anabolic or antiresorptive treatment alone. This enthusiasm has been tempered by the observations that the transition from daily bisphosphonate therapy may blunt the efficacy of teriparatide. By contrast, more recent studies suggest that once-weekly bisphosphonate therapy may provide a better option with parathyroid hormone either in combination or in sequence. These considerations are critical to understanding the benefits of sequential treatment (parathyroid hormone followed by an antiresorptive agent), which aims to maintain or build on the large gains in efficacy from short-term therapy with parathyroid hormone. Because patients may require an additional treatment course of parathyroid hormone in the future, the choice of antiresorptive agent should be carefully considered. In addition, more recent evidence suggests that the forms of parathyroid hormone may have important differences in action that influence combination and sequence outcomes. Summary: Combination and sequential therapy with parathyroid hormone offers new options to maximize efficacy in patients at risk for osteoporotic fracture.

AB - Purpose of review: The prevention and treatment of osteoporosis has traditionally involved the use of antiresorptive therapies. The introduction of parathyroid hormone, an anabolic agent that enhances bone formation, has been accompanied by new treatment strategies. This article reviews combination and sequential therapy approaches with parathyroid hormone and antiresorptive agents to optimize efficacy outcomes. Recent findings: The distinguishing features of the anabolic and antiresorptive therapies for the treatment of osteoporosis has led to the hypothesis that the appropriate use of both agents, either in sequence or in combination, may result in superior fracture protection compared with either anabolic or antiresorptive treatment alone. This enthusiasm has been tempered by the observations that the transition from daily bisphosphonate therapy may blunt the efficacy of teriparatide. By contrast, more recent studies suggest that once-weekly bisphosphonate therapy may provide a better option with parathyroid hormone either in combination or in sequence. These considerations are critical to understanding the benefits of sequential treatment (parathyroid hormone followed by an antiresorptive agent), which aims to maintain or build on the large gains in efficacy from short-term therapy with parathyroid hormone. Because patients may require an additional treatment course of parathyroid hormone in the future, the choice of antiresorptive agent should be carefully considered. In addition, more recent evidence suggests that the forms of parathyroid hormone may have important differences in action that influence combination and sequence outcomes. Summary: Combination and sequential therapy with parathyroid hormone offers new options to maximize efficacy in patients at risk for osteoporotic fracture.

KW - Anabolic agent

KW - Antiresorptive agent

KW - Combination therapy

KW - Parathyroid hormone

KW - Sequential therapy

UR - http://www.scopus.com/inward/record.url?scp=23044507489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044507489&partnerID=8YFLogxK

U2 - 10.1097/01.bor.0000166383.73153.cf

DO - 10.1097/01.bor.0000166383.73153.cf

M3 - Article

C2 - 15956845

AN - SCOPUS:23044507489

VL - 17

SP - 467

EP - 474

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 4

ER -